• Purity

  >90%, by SDS-PAGE under reducing conditions and visualized by silver stain

• Endotoxin Level

  <0.1 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by the ability of the immobilized protein to enhance the adhesion of Saos‑2 human osteosarcoma cells to human Fibronectin. When 3 x 10    ⁴ cells per well are added to rhNLRR-3 coated plates (5 μg/mL, 100 μL/well), approximately 50-70% will adhere after 1 hour at 37 °C.

• Source

  Mouse myeloma cell line, NS0-derived Val23-Thr628, with a C-terminal 6-His tag

• Accession #

• N-terminal Sequence    
  Analysis

  Val23

• Predicted Molecular Mass

  69.3 kDa

• SDS-PAGE

  90-95 kDa, reducing conditions

Background: LRRN3/NLRR-3

Neuronal leucine-rich repeat 3 (NLRR-3) is an 85 kDa, N-glycosylated member of a CNS-associated family of transmembrane molecules that includes AMIGO, FLRT, LINGO, LRIG, SLITRK, and Trk subgroups (1, 2). Mature human NLRR-3 consists of a 606 amino acid (aa) extracellular domain (ECD) with 13 LRRs, an RGD integrin-binding motif, one Ig-like domain, and one fibronectin type III-like domain, a 21 aa transmembrane segment, and a 59 aa cytoplasmic domain (3). Within the ECD, human NLRR-3 shares 91% aa sequence identity with mouse and rat NLRR-3. NLRR-3 is expressed in specific areas of the developing and adult CNS, and more weakly in other tissues including lung, liver, kidney, and adrenal gland (2 - 5). It is preferentially expressed in the third layer of the cerebral cortex in contrast to other NLRRs which are more diffusely distributed between cortical layers (6). During mouse development, its expression pattern is generally complementary to that of SLITRK6 in select brain regions, plus the cochlea, eye, tongue, teeth, and nasal mesenchyme (7). NLRR-3 is upregulated in the cerebral cortex following injury (3, 6). Its expression is dependent on NGF stimulation and is strongest in NGF responsive TrkA⁺ neuroblastoma cell lines that are weakly aggressive (3). The cytoplasmic domain of NLRR-3 contains two Yxxf motifs which are required for its clathrin-mediated internalization (8). The association of NLRR-3 with clathrin and beta -adaptin promotes the enhancement and prolongation of EGF induced signaling (8).

• References:

1. Chen, Y. et al. (2006) Brain Res. Rev. 51:265.

2. Haines, B.H. et al. (2005) Dev. Biol. 281:145.

3. Hamano, S. et al. (2004) Int. J. Oncol. 24:1457.

4. Taniguchi, H. et al. (1996) Brain Res. Mol. Brain Res. 36:45.

5. Fukamachi, K. et al. (2001) Biochem. Biophys. Res. Commun. 287:257.

6. Ishii, N. et al. (1996) Brain Res. Mol. Brain Res. 40:148.

7. Aruga, J. (2003) Gene Expr. Patterns 3:727.

8. Fukamachi, K. et al. (2002) J. Biol. Chem. 277:43549.

• Long Name:

  Leucine-rich Repeat Neuronal 1

• Entrez Gene IDs:

  54674 (Human); 16981 (Mouse); 81514 (Rat)

• Alternate Names:

  FIGLER5; immunoglobulin and leucine rich repeat domains 5; leucine rich repeat neuronal 3; leucine-rich repeat neuronal protein 3; leucine-rich repeat protein, neuronal 3; LRRN3; Neuronal leucine-rich repeat protein 3; NLRR3; NLRR-3